| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | 4-hydroxybutyrate receptor activity | 5.42e-06 | 2 | 47 | 2 | GO:0062124 | |
| GeneOntologyMolecularFunction | riboflavin transmembrane transporter activity | 8.09e-05 | 6 | 47 | 2 | GO:0032217 | |
| GeneOntologyMolecularFunction | vitamin transmembrane transporter activity | 8.26e-05 | 36 | 47 | 3 | GO:0090482 | |
| GeneOntologyMolecularFunction | phospholipase A2 activity | 8.98e-05 | 37 | 47 | 3 | GO:0004623 | |
| GeneOntologyMolecularFunction | calcium-independent phospholipase A2 activity | 1.93e-04 | 9 | 47 | 2 | GO:0047499 | |
| GeneOntologyBiologicalProcess | flavin-containing compound biosynthetic process | 5.06e-05 | 5 | 47 | 2 | GO:0042727 | |
| GeneOntologyBiologicalProcess | flavin adenine dinucleotide biosynthetic process | 5.06e-05 | 5 | 47 | 2 | GO:0072388 | |
| GeneOntologyBiologicalProcess | riboflavin metabolic process | 5.06e-05 | 5 | 47 | 2 | GO:0006771 | |
| GeneOntologyBiologicalProcess | flavin-containing compound metabolic process | 7.58e-05 | 6 | 47 | 2 | GO:0042726 | |
| GeneOntologyBiologicalProcess | flavin adenine dinucleotide metabolic process | 7.58e-05 | 6 | 47 | 2 | GO:0072387 | |
| GeneOntologyBiologicalProcess | riboflavin transport | 7.58e-05 | 6 | 47 | 2 | GO:0032218 | |
| GeneOntologyBiologicalProcess | organic anion transport | 1.54e-04 | 515 | 47 | 7 | GO:0015711 | |
| GeneOntologyBiologicalProcess | platelet activating factor metabolic process | 1.81e-04 | 9 | 47 | 2 | GO:0046469 | |
| GeneOntologyBiologicalProcess | vitamin transport | 2.82e-04 | 56 | 47 | 3 | GO:0051180 | |
| GeneOntologyBiologicalProcess | organophosphate biosynthetic process | 5.94e-04 | 644 | 47 | 7 | GO:0090407 | |
| GeneOntologyBiologicalProcess | phosphatidylcholine catabolic process | 5.98e-04 | 16 | 47 | 2 | GO:0034638 | |
| GeneOntologyBiologicalProcess | water-soluble vitamin metabolic process | 6.42e-04 | 74 | 47 | 3 | GO:0006767 | |
| GeneOntologyBiologicalProcess | low-density lipoprotein particle remodeling | 6.76e-04 | 17 | 47 | 2 | GO:0034374 | |
| Domain | Riboflavin_transptr | 1.86e-05 | 3 | 47 | 2 | IPR009357 | |
| Domain | DUF1011 | 1.86e-05 | 3 | 47 | 2 | PF06237 | |
| Domain | Quinoprotein_ADH-like_supfam | 3.20e-04 | 53 | 47 | 3 | IPR011047 | |
| Domain | Apc4_WD40_dom | 1.14e-03 | 20 | 47 | 2 | IPR024977 | |
| Domain | ANAPC4_WD40 | 1.14e-03 | 20 | 47 | 2 | PF12894 | |
| Domain | ER_TARGET | 6.23e-03 | 47 | 47 | 2 | PS00014 | |
| Pathway | WP_LIPID_METABOLISM_IN_SENESCENT_CELLS | 1.84e-05 | 20 | 37 | 3 | M45542 | |
| Pathway | KEGG_ETHER_LIPID_METABOLISM | 8.60e-05 | 33 | 37 | 3 | M2130 | |
| Pathway | REACTOME_VITAMIN_B2_RIBOFLAVIN_METABOLISM | 1.40e-04 | 7 | 37 | 2 | M27092 | |
| Pathway | REACTOME_VITAMIN_B2_RIBOFLAVIN_METABOLISM | 1.40e-04 | 7 | 37 | 2 | MM14770 | |
| Pathway | WP_RIBOFLAVIN_AND_COQ_DISORDERS | 5.98e-04 | 14 | 37 | 2 | M40065 | |
| Pubmed | Complete Deletion of Slc52a2 Causes Embryonic Lethality in Mice. | 1.87e-06 | 2 | 48 | 2 | 33518683 | |
| Pubmed | 1.87e-06 | 2 | 48 | 2 | 12740431 | ||
| Pubmed | Involvement of riboflavin transporter RFVT2/Slc52a2 in hepatic homeostasis of riboflavin in mice. | 1.87e-06 | 2 | 48 | 2 | 23911957 | |
| Pubmed | 1.87e-06 | 2 | 48 | 2 | 26791833 | ||
| Pubmed | 2.35e-06 | 19 | 48 | 3 | 9377118 | ||
| Pubmed | 5.59e-06 | 3 | 48 | 2 | 24139842 | ||
| Pubmed | 5.59e-06 | 3 | 48 | 2 | 23506902 | ||
| Pubmed | 5.59e-06 | 3 | 48 | 2 | 26976849 | ||
| Pubmed | The Expression of Riboflavin Transporters in Human Colorectal Cancer. | 5.59e-06 | 3 | 48 | 2 | 29715086 | |
| Pubmed | 5.59e-06 | 3 | 48 | 2 | 20463145 | ||
| Pubmed | 5.59e-06 | 3 | 48 | 2 | 26072523 | ||
| Pubmed | Mechanisms of prionSc- and HIV-1 gp120 induced neuronal cell death. | 6.27e-06 | 26 | 48 | 3 | 9745929 | |
| Pubmed | Allelic association analysis of phospholipase A2 genes with schizophrenia. | 1.12e-05 | 4 | 48 | 2 | 15318030 | |
| Pubmed | 2.79e-05 | 6 | 48 | 2 | 19267064 | ||
| Pubmed | 5.19e-05 | 8 | 48 | 2 | 15319294 | ||
| Pubmed | 1.22e-04 | 12 | 48 | 2 | 18161889 | ||
| Pubmed | Effect of riboflavin deficiency on development of the cerebral cortex in Slc52a3 knockout mice. | 1.22e-04 | 12 | 48 | 2 | 33116204 | |
| Pubmed | 2.50e-04 | 17 | 48 | 2 | 19424794 | ||
| Pubmed | Does 3D Phenotyping Yield Substantial Insights in the Genetics of the Mouse Mandible Shape? | 2.81e-04 | 18 | 48 | 2 | 26921296 | |
| Pubmed | 3.49e-04 | 20 | 48 | 2 | 30596474 | ||
| Pubmed | 4.23e-04 | 22 | 48 | 2 | 15084671 | ||
| Pubmed | 4.63e-04 | 23 | 48 | 2 | 17239249 | ||
| Pubmed | 4.79e-04 | 263 | 48 | 4 | 34702444 | ||
| Pubmed | Preterm birth in Caucasians is associated with coagulation and inflammation pathway gene variants. | 7.46e-04 | 128 | 48 | 3 | 18818748 | |
| Pubmed | Racial disparity in pathophysiologic pathways of preterm birth based on genetic variants. | 7.46e-04 | 128 | 48 | 3 | 19527514 | |
| Pubmed | 8.89e-04 | 136 | 48 | 3 | 25429064 | ||
| Pubmed | 1.08e-03 | 35 | 48 | 2 | 18992148 | ||
| Pubmed | Different evolutionary processes shaped the mouse and human olfactory receptor gene families. | 1.24e-03 | 340 | 48 | 4 | 11875048 | |
| Pubmed | 1.24e-03 | 340 | 48 | 4 | 11802173 | ||
| Pubmed | 1.28e-03 | 343 | 48 | 4 | 32295537 | ||
| Pubmed | 1.33e-03 | 346 | 48 | 4 | 14611657 | ||
| Cytoband | 4q21 | 2.01e-04 | 20 | 48 | 2 | 4q21 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr11q11 | 8.14e-04 | 40 | 48 | 2 | chr11q11 | |
| Cytoband | 11q11 | 1.12e-03 | 47 | 48 | 2 | 11q11 | |
| GeneFamily | Phospholipases | 7.89e-05 | 42 | 36 | 3 | 467 | |
| GeneFamily | Solute carriers | 1.17e-04 | 395 | 36 | 6 | 752 | |
| GeneFamily | Olfactory receptors, family 4 | 2.13e-03 | 129 | 36 | 3 | 151 | |
| Coexpression | GSE2770_IL12_ACT_VS_ACT_CD4_TCELL_6H_DN | 2.65e-05 | 192 | 48 | 5 | M6064 | |
| Coexpression | GSE3039_ALPHAALPHA_CD8_TCELL_VS_B2_BCELL_UP | 3.23e-05 | 200 | 48 | 5 | M6437 | |
| ToppCell | normal-na-Lymphocytic_B-B_mem-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 1.37e-06 | 182 | 47 | 5 | ee36ea6cb9a5a08aeb83f2b7a249255f0b1a9870 | |
| ToppCell | Control-Lymphoid_B-B_intermediate|Control / Disease group, lineage and cell class | 1.74e-06 | 191 | 47 | 5 | 0082181dbc39c7c4fd3aa34c3ed61439548e844b | |
| ToppCell | control-B_memory|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.78e-06 | 192 | 47 | 5 | d6ef271b6c4f9b49323650f3f773abd61c1b13c3 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.78e-06 | 192 | 47 | 5 | 89b8ebdc285ed3c0f807fd1157271130d37dfa41 | |
| ToppCell | Healthy/Control-B_intermediate|World / Disease group and Cell class | 1.78e-06 | 192 | 47 | 5 | 2266aa695955f5d885708e6bc0d5a8827c306223 | |
| ToppCell | healthy_donor-Lymphocytic-B_cell|healthy_donor / Disease condition, Lineage, Cell class and subclass | 1.78e-06 | 192 | 47 | 5 | 7d9e5772b6e531b50ed4e4d6304ef11235f27f37 | |
| ToppCell | healthy_donor-Lymphocytic-B_cell-|healthy_donor / Disease condition, Lineage, Cell class and subclass | 1.78e-06 | 192 | 47 | 5 | 975312f9d6cede4d4f5b737e481e5c73accc8c50 | |
| ToppCell | Healthy/Control-B_intermediate|Healthy/Control / Disease group and Cell class | 1.87e-06 | 194 | 47 | 5 | 8a4260eeccb4924c392798b1ffa23cdd3a4062e9 | |
| ToppCell | mild-B_memory|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.12e-06 | 199 | 47 | 5 | e6ac9a0959b0de2c6a99298feb7715aa80ade1dd | |
| ToppCell | mild-B_memory|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.12e-06 | 199 | 47 | 5 | 025bb65629d9e20c374e8f1ba08c36d1bb569190 | |
| ToppCell | droplet-Thymus-nan-24m-Lymphocytic-immature_T_cell|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.14e-05 | 132 | 47 | 4 | 9936078c328b1e1d59f9dfdd69d36926a0cdaf0d | |
| ToppCell | mild_COVID-19_(asymptomatic)-B_intermediate|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2) | 2.82e-05 | 166 | 47 | 4 | 8de8f388f24436b84e19ef460476fdbda4d16abf | |
| ToppCell | droplet-Liver-Npc-18m-Lymphocytic-B_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.95e-05 | 168 | 47 | 4 | ce9fae8b295c668b0959d5007a8bcd401d80e258 | |
| ToppCell | BAL-Control-cDC_6|Control / Compartment, Disease Groups and Clusters | 2.95e-05 | 168 | 47 | 4 | 65ec473cff748b334c0a66e33bc34a8465fe7631 | |
| ToppCell | droplet-Liver-Npc-18m-Lymphocytic-B_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.16e-05 | 171 | 47 | 4 | 584a095ddcbf78aa29527f84b46b5ad3e2edbaa9 | |
| ToppCell | facs-Marrow-B-cells-18m-Hematologic-Unknown_Progenitor|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.54e-05 | 176 | 47 | 4 | 5f9ae5eb45603ed0422a3a993ecdbe2ce05d6e45 | |
| ToppCell | facs-Marrow-B-cells-18m-Hematologic-hematopoietic_stem_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.62e-05 | 177 | 47 | 4 | 35d42b07d9c31528bf59199e361bb8a3bfbe3b75 | |
| ToppCell | droplet-Marrow-nan-18m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.78e-05 | 179 | 47 | 4 | 1757b9f3f4c634277a67c4f5a39d27d6b4937073 | |
| ToppCell | 5'-GW_trimst-2-SmallIntestine-Epithelial-neuro-epithelial-M/X_cells_(MLN/GHRL+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.95e-05 | 181 | 47 | 4 | cb17c904ab86d56dd30cac9b61acbb3b76f84ded | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_cell-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.12e-05 | 183 | 47 | 4 | 6086a862ab35bc683af44c03ee14cbb08ab99945 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_cell|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.12e-05 | 183 | 47 | 4 | f4f453692da77cef666cc281c4883c9c6b279fd4 | |
| ToppCell | droplet-Lung-nan-21m-Myeloid-alveolar_macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.39e-05 | 186 | 47 | 4 | 8f77e552e613b6e124443c7f6ef5c1316a5ff8db | |
| ToppCell | droplet-Lung-nan-21m-Myeloid-Alveolar_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.39e-05 | 186 | 47 | 4 | f1aa0c58336d23bcbe52a59e7af954d20085bdb6 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_memory-|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.48e-05 | 187 | 47 | 4 | 43f81863063509337bd56a67010c62fb51109bd5 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_memory|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.48e-05 | 187 | 47 | 4 | ea56cfca919a09db852b7ee5e42323f822962465 | |
| ToppCell | Control-Lymphoid_B-B_memory|Control / Disease group, lineage and cell class | 4.58e-05 | 188 | 47 | 4 | ba4245de3bee29118abab57c4fce60b2007a189c | |
| ToppCell | (1)_B_cell|World / immune cells in Peripheral Blood (logTPM normalization) | 4.58e-05 | 188 | 47 | 4 | 642a334f2d5b6dc9df4a9fa0558833bd37bd3c58 | |
| ToppCell | (10)_B_cell|World / immune cells in Peripheral Blood (logTPM normalization) | 4.58e-05 | 188 | 47 | 4 | fa1346902021c3a6557555ada0fd37b29cf9d5ec | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_memory|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.58e-05 | 188 | 47 | 4 | b6ae707b033a17c75ca81f9194631ead1b63d170 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.58e-05 | 188 | 47 | 4 | 9256c5f45c97df209bb9c322c3b557d4f726a333 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory-B_memory-0|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.58e-05 | 188 | 47 | 4 | 6f53bcd4caab2fc961af799039ea5c3ddae56781 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory-B_memory-3|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.67e-05 | 189 | 47 | 4 | ac0203f17b481d608587113ea2de0f383b29ed27 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_naive|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.77e-05 | 190 | 47 | 4 | e63945fa1dcd58bee129f1dd0c23b64a76241554 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_naive-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.77e-05 | 190 | 47 | 4 | fa65bc5a178ae0c80a9bd4b282e4539493128a64 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_activate-7|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.87e-05 | 191 | 47 | 4 | 2feab42ac6d29fa4eac78f3f78a5f8aa0a559523 | |
| ToppCell | Control-Lymphoid_B|Control / Disease group, lineage and cell class | 4.87e-05 | 191 | 47 | 4 | 0a760cd3a48c487ec899adb882fddea8914cfe0c | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.87e-05 | 191 | 47 | 4 | 03f6da73e7b706252d2096507222229c4101a27b | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.87e-05 | 191 | 47 | 4 | 8dda37ebf74b587129795f61541cc511ec97a314 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.87e-05 | 191 | 47 | 4 | 578b58782e816ecaeabfbc616ceb1dcd53ee428b | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.87e-05 | 191 | 47 | 4 | 5a9a592875fbd0b1429b48db29a760fdc9c2c856 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_memory|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.87e-05 | 191 | 47 | 4 | 22134a2c1a92208bc1629a620ce73a56502613c2 | |
| ToppCell | (100)_CD19+_Naive_B_cell|World / immune cells in Peripheral Blood (logTPM normalization) | 4.97e-05 | 192 | 47 | 4 | ae7e6ed7b6cc1dd45bc0547783515beecad7792a | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_memory-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.97e-05 | 192 | 47 | 4 | debd471f61cf3606b8e9c246add0be5df601af7f | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_mem-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.97e-05 | 192 | 47 | 4 | 80a71ab3434076803466ccac0df73468889c7dd3 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_mem|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.97e-05 | 192 | 47 | 4 | 75ce635d669ff77d1fd54e10467f21d5e5d67b08 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_memory|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.97e-05 | 192 | 47 | 4 | 314f74dd3c6d94839eed05b9a1a398217ef78029 | |
| ToppCell | Healthy_donor-B_intermediate|World / disease group, cell group and cell class (v2) | 4.97e-05 | 192 | 47 | 4 | f77007b284e11f8654ad599eef929df7c6c4ebf0 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_intermediate-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.97e-05 | 192 | 47 | 4 | f9f64ad7bab1433e9a45adb7db7f43ce3f591b47 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_intermediate|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.97e-05 | 192 | 47 | 4 | 4884fd8ffa6fd6c30d7ac6bf447456b3397eabc5 | |
| ToppCell | normal-na-Lymphocytic_B-B_cell-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.07e-05 | 193 | 47 | 4 | 4fbf559771c367a6f5a03e0a5ef33366c118ddbf | |
| ToppCell | normal-na-Lymphocytic_B|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.07e-05 | 193 | 47 | 4 | 5fe436b8da06c537b61d18aba8a24b0c8b1895bb | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-11|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.07e-05 | 193 | 47 | 4 | cf4ba50aa4a00d1ba22fc7626d49a4104377d5d9 | |
| ToppCell | normal-na-Lymphocytic_B-B_naive-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.07e-05 | 193 | 47 | 4 | dd199163fc13f3d411fe741cf003237064349e22 | |
| ToppCell | normal-na-Lymphocytic_B-B_cell|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.07e-05 | 193 | 47 | 4 | 2fd1cc050c775360cd53872fd405cf78288d7c4d | |
| ToppCell | Healthy_donor-B_intermediate|Healthy_donor / disease group, cell group and cell class (v2) | 5.07e-05 | 193 | 47 | 4 | e2be57bf3cbbbbff64853f06b9c11b136f73eea7 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_intermediate|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.07e-05 | 193 | 47 | 4 | 8f1d6024ef092923321e6efd441b8d476db70aed | |
| ToppCell | PBMC-Mild-Lymphocyte-B|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.17e-05 | 194 | 47 | 4 | b6328575eedb19e0ad7f4d03041672f3dc146da0 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.17e-05 | 194 | 47 | 4 | 2b61023a602d336ed0de174e9141046173db34e6 | |
| ToppCell | COVID-19_Moderate-B_naive|World / disease group, cell group and cell class | 5.17e-05 | 194 | 47 | 4 | 1f81d618799e482a36dce528bba70f52cc69a901 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.17e-05 | 194 | 47 | 4 | 60542304899b99caa38e4abf6b71ba986fa6c399 | |
| ToppCell | Control-Lymphoid_B-B_naive|Control / Disease group, lineage and cell class | 5.17e-05 | 194 | 47 | 4 | 4f9600960a287cfc020c06b4af3528d4e5797916 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_mem|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 5.17e-05 | 194 | 47 | 4 | 40c7f9bd69a8e843b81972e25a67f591021415dd | |
| ToppCell | COVID-19_Mild-Lymphoid_B-B_intermediate|COVID-19_Mild / Disease group, lineage and cell class | 5.17e-05 | 194 | 47 | 4 | bf6f72a489c62cbf1a679552d8c5eaaaa0b99d33 | |
| ToppCell | PBMC-Control-Lymphocyte-B|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.17e-05 | 194 | 47 | 4 | a8daf73c186a15adb9ea02793d4bd9cb35c66290 | |
| ToppCell | mild-Lymphocytic-B_cells_1|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 5.17e-05 | 194 | 47 | 4 | fad1986cba9cd23ac68e639d7335fbcd6ae2a4e7 | |
| ToppCell | PBMC-Mild-Lymphocyte-B|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.17e-05 | 194 | 47 | 4 | b16b96e42ea9734731342d4c41ff1711bd149462 | |
| ToppCell | PBMC-Control-Lymphocyte-B|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.17e-05 | 194 | 47 | 4 | 39121c7d537ac103f6959271d814fd327be7114f | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 5.17e-05 | 194 | 47 | 4 | f2486b19ac52a48d19f80b38a5536bee3dad745b | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.17e-05 | 194 | 47 | 4 | ad9a8cc57f54bdec4cd6990b2cace947b7a163c9 | |
| ToppCell | B_cells|World / Immune cells in Kidney/Urine in Lupus Nephritis | 5.17e-05 | 194 | 47 | 4 | 22b87fe2bb84632ddcef8f1d7742021728e2246d | |
| ToppCell | control-Lymphocytic-B_cells_1|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 5.27e-05 | 195 | 47 | 4 | ff7956624b36df34e55295b295a71585accf07bd | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_mem-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 5.27e-05 | 195 | 47 | 4 | 51e6cfecd66a874673d0b79a295489a358bddfd5 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.27e-05 | 195 | 47 | 4 | 07852aab50a2ece9938334301f0a9d7181da06b8 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-DC-DC3-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.27e-05 | 195 | 47 | 4 | d8fa96c8f14bd088c3f8bd14f894a2c5b7ad46a7 | |
| ToppCell | Healthy_donor-B_naive|World / disease group, cell group and cell class (v2) | 5.27e-05 | 195 | 47 | 4 | c66bbfdf0091cc62aa50edfa88820bbda191b7bb | |
| ToppCell | control-B_intermediate|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.27e-05 | 195 | 47 | 4 | ddbc924b1a08685da0ed0755856178bae99a75b9 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_naive|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.38e-05 | 196 | 47 | 4 | fcbfd8c4771d99a45fc53e482ef98edabe8ef591 | |
| ToppCell | mild_COVID-19-B_naive|mild_COVID-19 / disease group, cell group and cell class (v2) | 5.38e-05 | 196 | 47 | 4 | 00398079d3ac14dc2026c0cbd7388f1f3257b134 | |
| ToppCell | normal-na-Lymphocytic_B-B_mem|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.38e-05 | 196 | 47 | 4 | 97f06f1e79ef27c7b9305373ff203d1527fe12af | |
| ToppCell | normal-na-Lymphocytic_B-B_mem-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.38e-05 | 196 | 47 | 4 | e938d2f68f523432f93e7f9f26a00395a153a630 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_naive|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.38e-05 | 196 | 47 | 4 | f45cb8f714ae7ac800768df65f299b98a2d42962 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.38e-05 | 196 | 47 | 4 | 5e5928fc218859317860fc387928127ac8009ba8 | |
| ToppCell | Healthy_donor-B_naive|Healthy_donor / disease group, cell group and cell class (v2) | 5.38e-05 | 196 | 47 | 4 | cf254b1466357984201595fa32408d659eb741ef | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_naive-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 5.38e-05 | 196 | 47 | 4 | d7e6c89cb49933b4a86d26d15f6772f2481d37ef | |
| ToppCell | Healthy/Control-B_naive|World / Disease group and Cell class | 5.38e-05 | 196 | 47 | 4 | ec935a4e16495c87b17070eb13c1e28bdb64e7ee | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.49e-05 | 197 | 47 | 4 | f7a8440d2b8b17d9726c6fe3dd383effbfebab13 | |
| ToppCell | COVID-19_Mild-Lymphoid_B|COVID-19_Mild / Disease group, lineage and cell class | 5.49e-05 | 197 | 47 | 4 | ff25c0e184bd0f068014bc3f5eba3aee17511b87 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.49e-05 | 197 | 47 | 4 | 7cae4f3eabfebce101de7bb7defb17d6c5360b58 | |
| ToppCell | control-B_intermediate|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.60e-05 | 198 | 47 | 4 | e24345c8cec8c21f7b5163b7326ba8f83a587ce3 | |
| ToppCell | severe-B_memory|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.71e-05 | 199 | 47 | 4 | 6d3436dd65d525aaa23ec02672005380f21c4d0f | |
| ToppCell | COVID-19-COVID-19_Mild-Lymphocyte-B-B_intermediate|COVID-19_Mild / Disease, condition lineage and cell class | 5.71e-05 | 199 | 47 | 4 | 1c6a08d01f6c1a2a4b6587d3a4522efbd03275e1 | |
| ToppCell | COVID-19-COVID-19_Mild-Lymphocyte-B-B_memory|COVID-19_Mild / Disease, condition lineage and cell class | 5.71e-05 | 199 | 47 | 4 | 54e392b4ebe601d4838739ff7de3ac6b2203c948 | |
| ToppCell | Control-Control-Lymphocyte-B-B_intermediate|Control / Disease, condition lineage and cell class | 5.71e-05 | 199 | 47 | 4 | ee6f07eec7edfe41d2f7fcb0b509ce00e99a6a95 | |
| ToppCell | (01)_Cycling_Basal_(homeostasis)-(1)_24hpi|(01)_Cycling_Basal_(homeostasis) / shred by cell type and Timepoint | 5.81e-05 | 71 | 47 | 3 | 6aa56b0daaeb5e0ae30619f9c6945c8e42899b27 | |
| ToppCell | mild-B_intermediate|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.82e-05 | 200 | 47 | 4 | 8e3132a1fe3708f725c5c4077878fb87bbea3678 | |
| ToppCell | Control-Epithelial_alveolar-Mes-Like|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.49e-04 | 116 | 47 | 3 | df7609503782d8d7e4f31ed2a626916e5474d5bc | |
| ToppCell | Control-Epithelial_alveolar-Mes-Like-Differentiating_AT1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.25e-04 | 127 | 47 | 3 | 556aaf88719c83f307fa50dfac151136ed05c8ad | |
| ToppCell | droplet-Bladder-BLADDER-1m-Epithelial-nan|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.33e-04 | 140 | 47 | 3 | e442c46979d725ec82f525a001c46d971fcade4d | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_ascending_limb_epithelial_cell-Degenerative_Ascending_Thin_Limb_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.89e-04 | 146 | 47 | 3 | d33bd571c2adf5f89e6f02e77d094c19edd4729c | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_memory-B_memory-6|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.19e-04 | 149 | 47 | 3 | 2cd860b96ed4be4d26844085d464961c1418054a | |
| Disease | Brown-Vialetto-Van Laere syndrome (implicated_via_orthology) | 6.82e-06 | 3 | 45 | 2 | DOID:0050694 (implicated_via_orthology) | |
| Disease | melanoma | 3.74e-05 | 248 | 45 | 5 | C0025202 | |
| Disease | 5-oxoproline measurement | 2.69e-04 | 16 | 45 | 2 | EFO_0010988 | |
| Disease | Inborn Errors of Metabolism | 3.05e-04 | 17 | 45 | 2 | C0025521 | |
| Disease | urate measurement, bone density | 2.44e-03 | 619 | 45 | 5 | EFO_0003923, EFO_0004531 | |
| Disease | cognitive inhibition measurement | 2.66e-03 | 50 | 45 | 2 | EFO_0007969 | |
| Disease | serum metabolite measurement | 2.98e-03 | 945 | 45 | 6 | EFO_0005653 | |
| Disease | Respiratory Distress Syndrome, Adult | 3.21e-03 | 55 | 45 | 2 | C0035222 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| FLFLAVHEAWAGMLK | 11 | Q8N129 | |
| AMLGTGKLFWVFFLI | 6 | Q7Z6A9 | |
| GFGKSFNSLWMHGLL | 66 | Q9NP70 | |
| LLHFFLLATFTWMGL | 936 | Q86SQ4 | |
| GLWLALMAVHGAIFL | 51 | Q99678 | |
| MGWLFLKVLLAGVSF | 1 | Q96EG1 | |
| LLKWSFFGARVMHNL | 496 | Q8HWS3 | |
| LGIHLLWGTMKGQFF | 301 | Q15622 | |
| GLTFGHLKMVLLWAS | 291 | Q08AI8 | |
| LMLLAAWIGGFLHSL | 171 | Q8NGL6 | |
| LKGFAILSWIIGFLH | 141 | Q8NH43 | |
| KMLLGTWVGGFLHSI | 141 | Q8NH73 | |
| SHFIAWTGRGMEFKL | 351 | P50549 | |
| LHKLFVFGLMWSLGA | 2346 | Q96JB1 | |
| GSFHGLSSLKKLWVM | 236 | Q9HBW1 | |
| FHIHSLWMKRFLFGL | 626 | P59047 | |
| MKLASGFLVLWLSLG | 1 | Q9BX93 | |
| LKGWHKRFFVLDNGM | 101 | Q9BZF3 | |
| GLSKFLGTHWLMGNI | 106 | Q13093 | |
| NCFWHFGLLLKLGFL | 546 | Q96PB1 | |
| WLSEAGLRLLHFLFM | 291 | Q15131 | |
| FGGHKLLIFSSISWM | 296 | Q3MIR4 | |
| MLWFNFKLRVGFNHG | 1156 | O60503 | |
| MKNHLLFWGVLAVFI | 1 | P01591 | |
| MWLRSLLKPIHVFFG | 146 | Q8NBI2 | |
| GVKHMKFWTLAGSAL | 1526 | Q6ZMW3 | |
| WKLMGLIGGIHGFFL | 446 | Q504Y0 | |
| LHFLMGVWGSAFSIL | 386 | P47712 | |
| LRALWHKVMFPVFLG | 111 | P30711 | |
| VLFIHGLMGAAFKTW | 396 | Q96JX3 | |
| RGWKSFHGILKGMIL | 781 | A5PKW4 | |
| EKLHRAFAIWSGFGM | 271 | Q96LT4 | |
| MLLGGLAFAIQDWHI | 246 | Q8N4F4 | |
| LTHLLVALFGMGSWA | 11 | Q9HAB3 | |
| DGALLVNAMFFKPHW | 196 | P50454 | |
| EGIFLLANGLHMFLW | 916 | O94855 | |
| LSGKWLMHLAPGFKL | 166 | Q9H3H3 | |
| LLKNLGHWLGMITLA | 1191 | A5YKK6 | |
| DGILKMWKHEGFFAL | 281 | O95258 | |
| FWALVKLFSGPKHAM | 206 | Q92738 | |
| SAMKNGLWGHALLLA | 1636 | O15027 | |
| AGKHWGIAMLTIFLV | 266 | Q9UGH3 | |
| LTHLLVALFGMGSWA | 11 | Q9NWF4 | |
| LFHQLMLWKGDLKGV | 921 | Q8TEQ6 | |
| MGFAEAFLEHLWKNL | 1 | Q2M238 | |
| FFLALWGMVVGDKLL | 16 | P19224 | |
| AWEGLKRLGMITHLF | 941 | Q6ZQQ6 | |
| EGGMLHTFFKMAWLG | 221 | Q96M32 | |
| HTFFKMAWLGEIPAL | 226 | Q96M32 |